FDA approved a new indication for Breyanzi (lisocabtagene maraleucel) as the first CAR T-cell therapy in the U.S. for treatment of adults with marginal zone lymphoma who have failed treatment with or relapsed after two or more prior lines of therapy.
John C. Byrd grew up in Augusta, a town of 2,000 or so in northeastern Arkansas.
